{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T03:13:07Z","timestamp":1769569987387,"version":"3.49.0"},"reference-count":16,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T00:00:00Z","timestamp":1765065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to investigate the real\u2010world usage patterns and persistence rates of mirabegron and vibegron in the treatment of overactive bladder (OAB).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review was conducted on patients who received either mirabegron or vibegron as their initial treatment for OAB between August 2022 and December 2024. Two types of persistence rates were assessed: (1) the individual persistence for each drug (persistence rate I) and (2) the overall \u03b23\u2010adrenergic agonist persistence among patients who switched between mirabegron and vibegron (persistence rate II).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 192 patients were included, with 128 (66.7%) receiving mirabegron and 64 (33.3%) receiving vibegron. Mirabegron was more commonly prescribed to male patients. The median persistence rate I was 11\u2009months for mirabegron (95% CI, 6\u201316) and was not reached for vibegron (95% CI, 9\u2009months to not estimable) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.071). Among those who discontinued treatment, 40.7% of mirabegron users and 17.6% of vibegron users switched to the alternative \u03b23 agonist. The median persistence rate II was 16\u2009months for mirabegron (95% CI, 8\u201320) and not reached for vibegron (95% CI, 9\u2009months to not estimable) (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.352).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The higher discontinuation rate of mirabegron may reflect the availability of vibegron as an alternative treatment option. The complementary use of both \u03b23 agonists could play a key role in optimizing OAB management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70309","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T06:47:58Z","timestamp":1765176478000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Use and Persistence of Beta 3\u2010Adrenoceptor Agonists for the Treatment of Overactive Bladder"],"prefix":"10.1111","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9587-6798","authenticated-orcid":false,"given":"Naoki","family":"Wada","sequence":"first","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotona","family":"Miyauchi","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taichiro","family":"Ishimaru","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riku","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3306-9544","authenticated-orcid":false,"given":"Noriyuki","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyu","family":"Ohtani","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Numakura","sequence":"additional","affiliation":[{"name":"Department of Renal and Urologic Surgery Asahikawa Medical University  Asahikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,12,7]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177182.html."},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2023.02.003"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12480"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-024-04799-4"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.5489\/cuaj.3098"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2016.12.030"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25478"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13558"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2008.02177.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12475"},{"key":"e_1_2_11_12_1","article-title":"Long\u2010Term Efficacy and Safety of Vibegron Versus Mirabegron and Anticholinergics for Overactive Bladder: A Systematic Review and Network Meta\u2010Analysis","volume":"11","author":"Kennelly M.","year":"2022","journal-title":"Drugs in Context"},{"key":"e_1_2_11_13_1","first-page":"56","article-title":"Analysis of Urinary Retention Caused by Selective \u03b2 3\u2010Adrenoceptor Agonists Using the Japanese Adverse Drug Event Report Database (JADER)","volume":"78","author":"Kawazoe T.","year":"2023","journal-title":"Die Pharmazie"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12237"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12091"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.10.019"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001440"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70309","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T13:24:42Z","timestamp":1769520282000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1111\/iju.70309"],"URL":"https:\/\/doi.org\/10.1111\/iju.70309","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,7]]},"assertion":[{"value":"2025-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70309"}}